HPRHealth Psychology ResearchTBA2420-8124Health Psychology Research10.52965/001c.39576GeneralClinically Relevant Drug Interactions with Monoamine Oxidase   Inhibitorshttps://healthpr.org/journal/HPR/10/4/10.52965/001c.39576N. EdinofAmber,R. SwinfordConnor,S. OdishoAmira,R. BurroughsCaroline,W. StarkCain,A. RaslanWalid,M. CornettElyse,M. KayeAdam,D. KayeAlan20221042022-11-02Monoamine oxidase inhibitors (MAOI) are a class of drugs that were originally developed for the treatment of depression but have since been expanded to be used in management of affective and neurological disorders, as well as stroke and aging-related neurocognitive changes. Ranging from irreversible to reversible and selective to non-selective, these drugs target the monoamine oxidase (MAO) enzyme and prevent the oxidative deamination of various monoamines and catecholamines such as serotonin and dopamine, respectively. Tyramine is a potent releaser of norepinephrine (NE) and is found in high concentrations in foods such as aged cheeses and meats. Under normal conditions, NE is unable to accumulate to toxic levels due to the presence of MAO-A, an enzyme that degrades neurotransmitters, including NE. When MAO-A is inhibited, the capacity to handle tyramine intake from the diet is significantly reduced causing the brain to be vulnerable to overstimulation of postsynaptic adrenergic receptors with as little as 8-10 mg of tyramine ingested and can result in life-threatening blood pressure elevations. In addition to adverse reactions with certain foods, both older and newer MAOIs can negatively interact with both sympathomimetic and serotonergic drugs. In general, patients on a MAOI want to avoid two types of medications: those that can elevate blood pressure via sympathomimetic actions (e.g., phenylephrine and oxymetazoline) and those that can increase serotonin levels via 5-HT reuptake inhibition (e.g., dextromethorphan, chlorpheniramine, and brompheniramine). Illicit drugs that stimulate the central nervous system such as ecstasy (MDMA, 3,4-methylenedioxymethamphetamine) act as serotonin releasers. Patient involvement is also crucial to ensure any interaction within the healthcare setting includes making other providers aware of a MAOI prescription as well as avoiding certain OTC medications that can interact adversely with MAOIs.Monoamine oxidase inhibitors, drug interactions, hypertensive crisis, bleeding, ecstasy, weight gain, sexual dysfunction, insomnia, headache

1. Finberg JPM, Rabey JM. Inhibitors of MAO-A and MAO-B in psychiatry and neurology. Front Pharmacol. 2016;7. doi:10.3389/fphar.2016.00340 2. Youdim MBH, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci. 2006;7(4):295-309. doi:10.1038/nrn1883 3. Shulman KI, Herrmann N, Walker SE. Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs. 2013;27(10):789-797. doi:10.007/s40263-013-0097-3 4. Dezsi L, Vecsei L. Monoamine Oxidase B Inhibitors in Parkinson’s Disease. CNS Neurol Disord - Drug Targets. 2017;16(4). doi:10.2174/1871527316666170124165222 5. Edmondson DE, Binda C. Monoamine oxidases. In: Subcellular Biochemistry. Vol 87. Springer; 2018:117-139. doi:10.1007/978-981-10-7757-9_5 6. Finberg JPM. Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson’s disease. J Neural Transm. 2019;126(4):433-448. doi:10.1007/s00702-018-1952-7 7. Schatzberg AF. Safety and tolerability of antidepressants: Weighing the impact on treatment decisions. J Clin Psychiatry. Published online 2007. 8. Salter M, Kenney A. Myocardial Injury from Tranylcypromine-Induced Hypertensive Crisis Secondary to Excessive Tyramine Intake. Cardiovasc Toxicol. 2018;18(6):583-586. doi:10.1007/s12012-018-9476-9 9. Gillman PK. A reassessment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths. J Neural Transm. 2018;125(11):1707-1717. doi:10.1007/s00702-018-1932-y 10. Finberg JPM, Gillman K. Selective inhibitors of monoamine oxidase type B and the “cheese effect.” In: International Review of Neurobiology. Vol 100. Elsevier; 2011:169-190. doi:10.1016/b978-0-12-386467-3.00009-1 11. Gillman PK. A Review of Serotonin Toxicity Data: Implications for the Mechanisms of Antidepressant Drug Action. Biol Psychiatry. 2006;59(11):1046-1051. doi:10.1016/j.biopsych.2005.11.016 12. Thomas SJ, Shin M, McInnis MG, Bostwick JR. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: Strategies for the management of treatment-resistant depression. Pharmacotherapy. 2015;35(4):433-449. doi:10.1002/phar.1576 13. Wimbiscus M, Kostenko O, Malone D. MAO inhibitors: Risks, benefits, and lore. Cleve Clin J Med. 2010;77(12):859-882. doi:10.3949/ccjm.77a.09103 14. Flockhart DA. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: An update. J Clin Psychiatry. 2012;73(suppl 1):17-24. doi:10.4088/jcp.11096su1c.03 15. Finberg JPM. Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: Focus on modulation of CNS monoamine neurotransmitter release. Pharmacol Ther. 2014;143(2):133-152. doi:10.1016/j.pharmthera.2014.02.010 16. Bied AM, Kim J, Schwartz TL. A critical appraisal of the selegiline transdermal system for major depressive disorder. Expert Rev Clin Pharmacol. 2015;8(6):673-681. doi:10.1586/17512433.2016.1093416 17. Lee KC, Chen JJ. Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat. Published online 2007. 18. Lippman SB, Nash K. Monoamine Oxidase Inhibitor Update: Potential Adverse Food and Drug Interactions. Drug Saf. 1990;5(3):195-204. doi:10.2165/00002018-199005030-00004 19. Wiers CE, Cabrera E, Skarda E, Volkow ND, Wang GJ. PET imaging for addiction medicine: From neural mechanisms to clinical considerations. In: Progress in Brain Research. Vol 224. Elsevier B.V.; 2016:175-201. doi:10.1016/bs.pbr.2015.07.016 20. Fowler JS, Logan J, Shumay E, Alia-Klein N, Wang GJ, Volkow ND. Monoamine oxidase: radiotracer chemistry and human studies. J Label Compd Radiopharm. 2015;58(3):51-64. doi:10.1002/jlcr.3247 21. Finberg JPM, Youdim MBH. Selective mao a and b inhibitors: Their mechanism of action and pharmacology. Neuropharmacology. 1983;22(3 PART 2):441-446. doi:10.1016/0028-3908(83)90194-6 22. Sub Laban T, Saadabadi A. Monoamine Oxidase Inhibitors (MAOI). StatPearls Publishing; 2020. 23. Quitkin FM, Stewart JW, McGrath PJ, et al. Phenelzine versus imipramine in the treatment of probable atypical depression: Defining syndrome boundaries of selective MAOI responders. Am J Psychiatry. 1988;145(3):306-311. doi:10.1176/ajp.145.3.306 24. Keck PE, McElroy SL. New uses for antidepressants: Social phobia. J Clin Psychiatry. 1997;58(SUPPL. 14):32-36. 25. Schneier FR. Treatment of social phobia with antidepressants. J Clin Psychiatry. 2001;62(SUPPL. 1):43-48. 26. Regier DA, Kuhl EA, Kupfer DJ. The DSM-5: Classification and criteria changes. World Psychiatry. 2013;12(2):92-98. doi:10.1002/wps.20050 27. Sareen J, Stein M. A review of the epidemiology and approaches to the treatment of social anxiety disorder. Drugs. 2000;59(3):497-509. doi:10.2165/00003495-200059030-00007 28. Heimberg RG, Liebowitz MR, Hope DA, et al. Cognitive behavioral group therapy vs phenelzine therapy for social phobia 12-week outcome. Arch Gen Psychiatry. 1998;55(12):1133-1141. doi:10.1001/archpsyc.55.12.1133 29. UCSF Parkinson’s Disease Clinic and Research Center. Monoamine Oxidase B (MAO-B) Inhibitors | Parkinson’s Disease Clinic and Research Center. 30. Marsh L. Depression and parkinson’s disease: Current knowledge topical collection on movement disorders. Curr Neurol Neurosci Rep. 2013;13(12):1-9. doi:10.1007/s11910-013-0409-5 31. Fava M. New approaches to the treatment of refractory depression. J Clin Psychiatry. Published online 2000. 32. Nutt D, Glue P. Monoamine oxidase inhibitors: Rehabilitation from recent research? Br J Psychiatry. 1989;154(3):287-291. doi:10.1192/bjp.154.3.287 33. Petersen T, Dording C, Neault NB, et al. A survey of prescribing practices in the treatment of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(1):177-187. doi:10.1016/s0278-5846(01)00250-0 34. Olfson M, Klerman GL. Trends in the prescription of antidepressants by office-based psychiatrists. Am J Psychiatry. 1993;150(4):571-577. doi:10.1176/ajp.150.4.571 35. Olfson M, Marcus SC, Pincus HA, Zito JM, Thompson JW, Zarin DA. Antidepressant prescribing practices of outpatient psychiatrists. Arch Gen Psychiatry. 1998;55(4). doi:10.1001/archpsyc.55.4.310 36. Bleakley S. Antidepressant drug interactions: Evidence and clinical significance. Prog Neurol Psychiatry. 2016;20(3):21-27. doi:10.1002/pnp.429 37. Thase ME. Recognition and diagnosis of atypical depression. J Clin Psychiatry. Published online 2007. 38. Bartlett D. Drug-induced serotonin syndrome. Crit Care Nurse. 2017;37(1):49-54. doi:10.4037/ccn201769 39. Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ. 2014;348(feb19 6):g1626. doi:10.1136/bmj.g1626 40. Pedavally S, Fugate JE, Rabinstein AA. Serotonin syndrome in the intensive care unit: Clinical presentations and precipitating medications. Neurocrit Care. 2013;21(1):108-113. doi:10.1007/s12028-013-9914-2 41. Sampson E, Warner JP. Serotonin syndrome: Potentially fatal but difficult to recognize. Br J Gen Pract. Published online 1999. 42. Martin TG. Serotonin syndrome. Ann Emerg Med. 1996;28(5):520-526. doi:10.1016/s0196-0644(96)70116-6 43. Krishnamoorthy S, Ma Z, Zhang G, Wei J, Auerbach SB, Tao R. Involvement of 5-HT2A receptors in the serotonin (5-HT) syndrome caused by excessive 5-HT efflux in rat brain. Basic Clin Pharmacol Toxicol. 2010;107(4):830-841. doi:10.1111/j.1742-7843.2010.00586.x 44. Francescangeli J, Karamchandani K, Powell M, Bonavia A. The serotonin syndrome: From molecular mechanisms to clinical practice. Int J Mol Sci. 2019;20(9):2288. doi:10.3390/ijms20092288 45. BARTHOLOMEW AA. An evaluation of tranylcypromine (“Parnate”) in the treatment of depression. Med J Aust. 1962;1(18):655-662. doi:10.5694/j.1326-5377.1962.tb26247.x 46. Davidson J, Turnbull C. Isocarboxazid. Efficacy and tolerance. J Affect Disord. 1983;5(2):183-189. doi:10.1016/0165-0327(83)90012-5 47. Escobar JI, Schiele BC, Zimmerman R. The tranylcypromine isomers: a controlled clinical trial. Am J Psychiatry. 1974;131(9):1025-1026. doi:10.1176/ajp.131.9.1025 48. Evans DL, Davidson J, Raft D. Early and late side effects of phenelzine. J Clin Psychopharmacol. 1982;2(3):208-210. doi:10.1097/00004714-198206000-00007 49. Fulton B, Benfield P, Chouinard G, et al. Moclobemide. An update of its pharmacological properties and therapeutic use. Drugs. 1996;52(3):450-474. doi:10.2165/00003495-199652030-00013 50. Anderson IM, Nutt DJ, Deakin JFW. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 1993 British Association for Psychopharmacology guidelines. J Psychopharmacol (Oxf). 2000;14(1):3-20. doi:10.1177/026988110001400101 51. Winokur A, Gary KA, Rodner S, Rae-Red C, Fernando AT, Szuba MP. Depression, sleep physiology, and antidepressant drugs. Depress Anxiety. 2001;14(1):19-28. doi:10.1002/da.1043 52. Cantú TG, Korek JS. Monoamine oxidase inhibitors and weight gain. Drug Intell Clin Pharm. 1988;22(10):755-759. doi:10.1177/106002808802201002 53. Drieling T, Biedermann N, Schärer L, Langosch J. Psychotropic drug-induced change of weight: a review. Pharmacopsychiatry. 2005;38(5). doi:10.1055/s-2005-918667 54. Rabkin J, Quitkin F, Harrison W, Tricamo E, McGrath P. Adverse reactions to monoamine oxidase inhibitors. Part I. A comparative study. J Clin Psychopharmacol. 1984;4(5):270-278. doi:10.1097/00004714-198410000-00007 55. Rodriguez MA, Kumar SK, De Caro M. Hypertensive crisis. Cardiol Rev. 2010;18(2):102-107. doi:10.1097/crd.0b013e3181c307b7 56. Stahl SM, Felker A. Monoamine oxidase inhibitors: A modern guide to an unrequited class of antidepressants. CNS Spectr. 2008;13(10):855-871. doi:10.1017/s1092852900016965 57. Sathyanarayana Rao TS, Yeragani VK. Hypertensive crisis and cheese. Indian J Psychiatry. 2009;51(1):65. doi:10.4103/0019-5545.44910 58. Robinson DS. Monoamine oxidase inhibitors: a new generation. Psychopharmacol Bull. Published online 2002. 59. Horwitz D, Lovenberg W, Engelman K, Sjoerdsma A. Monoamine Oxidase Inhibitors, Tyramine, and Cheese. JAMA J Am Med Assoc. 1964;188(13). doi:10.1001/jama.1964.03060390010002 60. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd ed.; 2008. 61. McCabe B, Tsuang MT. Dietary consideration in MAO inhibitor regimens. J Clin Psychiatry. Published online 1982. 62. Da Prada M, Zürcher G, Wüthrich I, Haefely WE. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm Suppl. Published online 1988. 63. Shulman KI, Walker SE, MacKenzie S, Knowles S. Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. J Clin Psychopharmacol. 1989;9(6):397-402. doi:10.1097/00004714-198912000-00002 64. Shulman KI, Walker SE. Refining the MAOI diet: Tyramine content of pizzas and soy products. J Clin Psychiatry. 1999;60(3):191-193. doi:10.4088/jcp.v60n0308 65. Kaneko T, Ishigatsubo Y. Isoniazid and Food Interactions: Fish, Cheese, and Wine. Intern Med. 2005;44(11):1120-1121. doi:10.2169/internalmedicine.44.1120 66. Erne P, Bolli P, Bertel O, et al. Factors influencing the hypotensive effects of calcium antagonists. Hypertension. 1983;5(4_pt_2). doi:10.1161/01.hyp.5.4_pt_2.ii97 67. Taburet AM, Singlas E, Colin JN, Banzet O, Thibonnier M, Corvol P. Pharmacokinetic studies of nifedipine tablet: correlation with antihypertensive effects. Hypertension. 1983;5(4_pt_2). doi:10.1161/01.hyp.5.4_pt_2.ii29 68. Mallinger AG, Smith E. Pharmacokinetics of monoamine oxidase inhibitors. Psychopharmacol Bull. Published online 1991. 69. Baker GB, Urichuk LJ, McKenna KF, Kennedy SH. Metabolism of monoamine oxidase inhibitors. Cell Mol Neurobiol. 1999;19(3):411-426. doi:10.1023/a:1006982732681 70. Asnis GM, Henderson MA. EMSAM (deprenyl patch): How a promising antidepressant was underutilized. Neuropsychiatr Dis Treat. Published online October 2014:1911. doi:10.2147/ndt.s59107 71. DARLING HF. Chlorprothixine (Taractan) and isocarboxazid (Marplan) in psychotic depressions. Am J Psychiatry. 1961;117(10):931-932. doi:10.1176/ajp.117.10.931 72. Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: A review of postmarketing data. Clin Infect Dis. 2006;42(11):1578-1583. doi:10.1086/503839 73. Laine K, Anttila M, Helminen A, Karnani H, Huupponen R. Dose linearity study of selegiline pharmacokinetics after oral administration: Evidence for strong drug interaction with female sex steroids. Br J Clin Pharmacol. 1999;47(3):249-254. doi:10.1046/j.1365-2125.1999.00891.x 74. Krishnan KR. Revisiting monoamine oxidase inhibitors. J Clin Psychiatry. Published online 2007. 75. Hodgman MJ, Martin TG, Krenzelok EP. Serotonin syndrome due to venlafaxine and maintenance tranylcypromine therapy. Hum Exp Toxicol. 1997;16(1):14-17. doi:10.1177/0960327197016001031 76. Brubacher JR, Hoffman RS, Lurin MJ. Serotonin syndrome from venlafaxine-tranylcypromine interaction. Vet Hum Toxicol. Published online 1996. 77. Keltner N. Serotonin Syndrome: A Case of Fatal SSRI/MAOI Interaction. Perspect Psychiatr Care. 2009;30(4):26-31. doi:10.1111/j.1744-6163.1994.tb00446.x 78. Neuvonen PJ, Pohjola-Sintonen S, Tacke U, Vuori E. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. The Lancet. 1993;342(8884):1419. doi:10.1016/0140-6736(93)92774-n 79. Rapaport MH. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: The state of the art. J Clin Psychiatry. Published online 2007. 80. Keks N, Hope J, Keogh S. Switching and stopping antidepressants. Aust Prescr. 2016;39(3). doi:10.18773/austprescr.2016.039 81. Young JPR, Lader MH, Hughes WC. Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment in depressed outpatients. Br Med J. 1979;2(6201):1315-1317. doi:10.1136/bmj.2.6201.1315 82. Spiker DG, Pugh DD. Combining Tricyclic and Monoamine Oxidase Inhibitor Antidepressants. Arch Gen Psychiatry. 1976;33(7):828. doi:10.1001/archpsyc.1976.01770070058005 83. O’Brien S, McKeon P, O’Regan M. The efficacy and tolerability of combined antidepressant treatment in different depressive subgroups. Br J Psychiatry. 1993;162(3):363-368. doi:10.1192/bjp.162.3.363 84. Schipper P, Vanmolkot L, Peeters FPML. Combining a classic monoamine oxidase inhibitor with a tricyclic antidepressant in therapy-resistant depression: A case report and literature review. Tijdschr Voor Psychiatr. Published online 2016. 85. Grady MM, Stahl SM. Practical guide for prescribing MAOIs: Debunking myths and removing barriers. CNS Spectr. 2012;17(1):2-10. doi:10.1017/s109285291200003x 86. Amsterdam JD, Kim TT. Relative Effectiveness of Monoamine Oxidase Inhibitor and Tricyclic Antidepressant Combination Therapy for Treatment-Resistant Depression. J Clin Psychopharmacol. 2019;39(6):649-652. doi:10.1097/jcp.0000000000001130 87. Pittenger C, Bloch MH. Pharmacological treatment of obsessive-compulsive disorder. Psychiatr Clin North Am. 2014;37(3):375-391. doi:10.1016/j.psc.2014.05.006 88. Baker GB, Coutts RT, McKenna KF, Sherry-McKenna RL. Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: A review. J Psychiatry Neurosci. Published online 1992. 89. Marangell LB. Switching antidepressants for treatment-resistant major depression. J Clin Psychiatry. Published online 2001. 90. Gitlin MJ. Venlafaxine, monoamine oxidase inhibitors, and the serotonin syndrome. J Clin Psychopharmacol. 1997;17(1):66-67. doi:10.1097/00004714-199702000-00022 91. Reid JL. Alpha-adrenergic receptors and blood pressure control. Am J Cardiol. 1986;57(9):E6-E12. doi:10.1016/0002-9149(86)90716-2 92. Gillman PK. Serotonin syndrome: History and risk. Fundam Clin Pharmacol. 1998;12(5):482-491. doi:10.1111/j.1472-8206.1998.tb00976.x 93. Otte W, Birkenhager TK, Van den Broek WW. Fatal interaction between tranylcypromine and imipramine. Eur Psychiatry. 2003;18(5):264-265. doi:10.1016/s0924-9338(03)00090-7 94. Power BM, Pinder M, Hackett LP, Ilett KF. Fatal serotonin syndrome following a combined overdose of moclobemide, clomipramine and fluoxetine. Anaesth Intensive Care. 1995;23(4):499-502. doi:10.1177/0310057x9502300418 95. Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol (Oxf). 1999;13(1):100-109. doi:10.1177/026988119901300111 96. Isbister GK, Buckley NA, Whyte IM. Serotonin toxicity: A practical approach to diagnosis and treatment. Med J Aust. 2007;187(6):361-365. doi:10.5694/j.1326-5377.2007.tb01282.x 97. Antal EJ, Hendershot PE, Batts DH, Sheu WP, Hopkins NK, Donaldson KM. Linezolid, a novel oxazolidinone antibiotic: Assessment of monoamine oxidase inhibition using pressor response to oral tyramine. J Clin Pharmacol. 2001;41(5):552-562. doi:10.1177/00912700122010294 98. S.M. H, T. F, M. G. Linezolid: A review of its properties, function, and use in critical care. Drug Des Devel Ther. Published online 2018. 99. Vuori E, Henry JA, Ojanperä I, et al. Death following ingestion of MDMA (ecstasy) and moclobemide. Addiction. 2003;98(3):365-368. doi:10.1046/j.1360-0443.2003.00292.x 100. Silins E, Copeland J, Dillon P. Qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other serotonergic substances: Hierarchy of risk. Aust N Z J Psychiatry. 2007;41(8):649-655. doi:10.1080/00048670701449237 101. Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth. 2005;95(4):434-441. doi:10.1093/bja/aei210 102. Ener RA, Meglathery SB, Van Decker WA, Gallagher RM. Serotonin syndrome and other serotonergic disorders. Pain Med. 2003;4(1):63-74. doi:10.1046/j.1526-4637.2003.03005.x 103. Devine RM, van Heerden JA, Grant CS, Muir JJ. The role of methylene blue infusion in the management of persistent or recurrent hyperparathyroidism. Surgery. Published online 1983. doi:10.5555/uri:pii:0039606083903999 104. Krogh C. Compendium of pharmaceuticals and specialties. Can Med Assoc J. Published online 1983. 105. Ramsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity: Inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol. 2007;152(6):946-951. doi:10.1038/sj.bjp.0707430 106. Gillman PK. Methylene blue implicated in potentially fatal serotonin toxicity. Anaesthesia. 2006;61(10):1013-1014. doi:10.1111/j.1365-2044.2006.04808.x 107. Callaway NL, Riha PD, Bruchey AK, Munshi Z, Gonzalez-Lima F. Methylene blue improves brain oxidative metabolism and memory retention in rats. Pharmacol Biochem Behav. 2004;77(1):175-181. doi:10.1016/j.pbb.2003.10.007 108. Kita T, Sakaeda T, Baba T, et al. Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors. Biol Pharm Bull. 2003;26(3):386-390. doi:10.1248/bpb.26.386 109. Schoerlin MP, Mayersohn M, Hoevels B, Eggers H, Dellenbach M, Pfefen JP. Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide. Clin Pharmacol Ther. 1991;49(1):32-38. doi:10.1038/clpt.1991.6